This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Halozyme Therapeutics (HALO) Down 3.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the Invesco Biotechnology & Genome (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Regeneron (REGN) Gains 13% in 1 Month on FDA Nod For Eylea HD
by Zacks Equity Research
Regeneron (REGN) gains 13% in a month on the FDA's approval of a higher dose of Eylea and other positive updates.
Outlook's (OTLK) Shares Decline on CRL for Wet AMD Candidate
by Zacks Equity Research
Outlook's (OTLK) shares decline as it receives a complete response letter for Lytenava (ONS-5010), treating wet age-related macular degeneration.
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca
by Zacks Equity Research
Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca are part of the Zacks top Analyst Blog.
Oncology Market's Huge Potential Puts These Stocks in Focus
by Sanghamitra Saha
The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meaningful contributions in cancer treatment.
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics
by Zacks Equity Research
Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog.
Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More
by Zacks Equity Research
Regulatory updates from Regeneron (REGN) and Apellis (APLS) are in focus in the biotech sector.
Regeneron (REGN) Gets FDA Nod for Higher Dose of Eylea
by Zacks Equity Research
Regeneron (REGN) obtains FDA approval for a higher dose of aflibercept injection under the brand name Eylea HD for various ophthalmology indications. The regulatory body also approves Veopoz.
Regeneron's (REGN) Application for Blood Cancer Drug Accepted
by Zacks Equity Research
Regeneron's (REGN) application seeking approval of odronextamab for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma gets accepted for review in the EU.
Pharma Stock Roundup: FDA Okays PFE & JNJ Drugs, EU Approves ABBV's Migraine Drug
by Kinjel Shah
FDA approves Pfizer's (PFE) Elrexfio (elranatamab) for RRMM and J&J's (JNJ) oral combination tablet, Akeega to treat BRCA-positive mCRPC. European Commission approves AbbVie's (ABBV) Aquipta for migraine.
Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News
by Zacks Equity Research
Regulatory updates from SAGE and Galera (GRTX) are in focus in the biotech sector.
Regeneron (REGN) to Buy Decibel, Gains on Hearing Loss Therapies
by Zacks Equity Research
Regeneron (REGN) further builds upon its collaboration with Decibel by acquiring the company to expand its gene therapy programs for hearing loss.
Bayer (BAYRY) Q2 Earnings Miss Estimates, '23 Outlook Lowered
by Zacks Equity Research
Bayer (BAYRY) misses earnings and sales estimates in the second quarter of 2023 due to lower volumes and decreased prices for glyphosate-based products. Management lowers its guidance.
Alnylam (ALNY) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Alnylam (ALNY) reports weaker-than-expected second-quarter results. The company also provides updates on its pipeline candidates, which are being developed in collaboration with other pharma bigwigs.
Intellia (NTLA) Misses on Q2 Earnings, Gives Pipeline Update
by Zacks Equity Research
Intellia's (NTLA) second-quarter earnings miss estimates. The company provides an update on its gene-editing pipeline.
Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Ultragenyx (RARE) reports mixed second-quarter 2023 results, maintaining its 2023 financial guidance. The company's pipeline progress is also on track.
Regeneron (REGN) Q2 Earnings & Sales Top, Eylea Sales Decline
by Zacks Equity Research
Regeneron (REGN) beats earnings and sales estimates in second-quarter 2023 fueled by Dupixent. However, sales of the lead drug, Eylea, decline yet again.
Regeneron (REGN) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 3.23% and 4.77%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Regeneron (REGN) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Investors' focus is likely to be on the performance of lead drugs Eylea and Dupixent when Regeneron (REGN) reports its second-quarter 2023 results.
Sanofi (SNY) Beats on Q2 Earnings, Misses Sales, Stock Down
by Zacks Equity Research
Sanofi (SNY) beats second-quarter estimates for earnings but misses the same for sales. It raises the projected earnings growth range for 2023.
Roche (RHHBY) 1H Revenues, Earnings Down on Lower COVID-19 Test Sales
by Zacks Equity Research
Roche's (RHHBY) performance in the first half of 2023 was ordinary as COVID-19-test sales continue to decline and dent the top line.
Should First Trust NASDAQ-100 Equal Weighted ETF (QQEW) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQEW
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT